Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584793 | 0.89 | STAT3 (0.52) | STAT3STAT1PPARGPPARATERT | |
| Hydrochloric Acid SCHEMBL584374 | 0.88 | STAT3 (0.51) | STAT3STAT1PPARGPPARATERT | |
| Hydrochloric Acid SCHEMBL29883333 | 0.88 | STAT3 (0.51) | STAT3STAT1PPARGPPARATERT | |
| Exeporfinium SCHEMBL585997 | 0.88 | STAT3 (0.52) | STAT3STAT1TERT | |
| Exeporfinium SCHEMBL584418 | 0.87 | STAT3 (0.51) | STAT3STAT1TERT | |
| Exeporfinium SCHEMBL5012396 | 0.87 | STAT3 (0.51) | STAT3STAT1TERT | |
| SCHEMBL585880 | 0.86 | STAT3 (0.41) | STAT3STAT1 | |
| Hydrochloric Acid SCHEMBL583840 | 0.85 | STAT3 (0.40) | STAT3STAT1TERT | |
| SCHEMBL10084843 | 0.85 | STAT3 (0.40) | STAT3STAT1 | |
| Hydrochloric Acid SCHEMBL29648896 | 0.85 | STAT3 (0.48) | STAT3STAT1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | PPOX, PPIF, TYR | STAT3 2340/4885STAT1 1254/4885PPARG 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.